Soluble, partially purified, histocompati-
tocompatibility-2a antigens as well as alloantigenic specificities that were detected serologically. Another soluble fraction did not induce enhancement; this fraction has been shown to contain antigens other than H-2.
Passive enhancement of both tumors was achieved with antisera produced in allogeneic mice that were inoculated with crude membrane material or with a fraction obtained by Sephadex G-150 chromatography. These antisera contained cytotoxic and/or hemagglutinating antibodies. Immunologic enhancement was specific. A readily enhanceable tumor, Py 89, of C57BL origin was not enhanced with anti-H-2a antisera.
These results suggest strongly that all important H-2a transplantation antigenic determinants of spleen cells can be recovered by partial papain digestion and fractionation on a Sephadex G-150 colunin.
Mouse histocompatibility antigens are membrane-bound; they elicit transplantation immunity and are controlled by multiple genetic loci. The major histocompatibility locus of the mouse, H-2, has more than 20 known alleles; each allele determines a different combination of antigenic specificities (1) . Although solubilization and extensive purification of histocompatibility antigens of certain H-2 genotypes have been achieved, antigenic acitivity has been monitored, to the present, principally by serologic methods (2) (3) (4) . A major concern, therefore, is whether antigens detected serologically are able to elicit specific immunity with consequent graft rejection.
We have shown (5) that fractionation of papain-solubilized cell membranes obtained from strain A/J (H-25) spleen cells, using Sephadex G-150, yielded three fractions, monitored by 280-nm absorbance; fraction 1, in the excluded volume and fractions 2 and 3 in the included volume. All fractions were tested for alloantigenic activity by an in vitro assay: inhibition of immune cytolysis of lymph node cells labeled with 51Cr; in addition, the three fractions were assayed for the presence of transplantation antigens by an examination of their ability to elicit transplantation immunity both in noncongenic strains of mice that differ at H-2 and other loci and in congenic strains of mice, which differ only at the H-2 locus. It was found that all of the H-2 serologic specificities assayed were confined to a single peak (fraction 2); only this fraction accelerated skin-graft rejection in the congenic strains of mice that differ at the H-2 locus. The activity of the F2 fraction was found to be immunologically specific. The association of H-2 alloantigenic specificities (tested in vitro) and transplantation antigens (tested in vivo) with fraction F2, strongly suggests that both the serological specificities and the transplantation antigens are located either on the same molecules or on molecules of similar molecular weight. Our studies did not provide critical evidence for the completeness of the antigen. The techniques used may detect haptens as well as complete antigens.
In this study, we have assayed the biologic capacities of our solubilized-membrane materials to induce immunologic enhancement, that is the prolonged growth and survival of tumor allografts due to the presence in the graft recipient of alloantibodies directed against the alloantigens of the graft donor. Present evidence suggests strongly that in order to achieve enhancement, the appropriate alloantibodies must combine with all the determinants of the transplantation antigens (6, 7) . Specific immunologic enhancement is therefore a test for completeness of the antigen. This report describes the effects of the F2 and F3 fractions as well as crude membrane preparations from A/J (H-25) spleen cells on the growth and regression of two A/J strain tumors: YAA-C1 grafted in CBA (H-2k) mice and Sarcoma I grafted in mice of the B10.D2 (H-2d) strain.
MATERIALS AND METHODS
Antigenic Materials. Preparation of the crude membrane material and treatment with papain were performed as described (5) . Batches of 1000 spleens from A/J mice have been routinely used as a starting material and the papain-solubilized material, after concentration by ultrafiltration, was chromatographed on a Sephadex G-150 column (2.5 X 160 cm), maintained at 40C. H-2 alloantigenic specificities measured as described (5) (8) with crystalline plasma albumin as a standard.
Mice. A/J (H-2a) and B1O.D2 (H-2d) strains of mice were purchased from the Jackson Laboratory, Bar Harbor, Me. CBA (H-2k) mice were taken from stocks maintained in our laboratory. The original nucleus of this stock was obtained from Dr. A. C. Allison, the National Institute for Medical Research, London, and has been maintained by strict brothersister matings. Additional strains of mice used in the antigenic specificity studies were BALB/c and C3Hf/Lw; both strains were raised in our own colony. These mice were used in the production of antisera.
Antibody Titrations. Sera of CBA and B1O.D2 mice that were injected with antigenic material were assayed for cytotoxic and hemagglutinating antibodies at the times indicated in the tables and text.
Diluted sera were incubated for 30 min at room temperature, with 5 X 104 A/J lymph node target cells that were labeled with 51Cr. Absorbed guinea pig complement was then added and incubation was continued for an additional 90 min. Release of 51Cr was measured by an automatic gamma-cell counter (Nuclear-Chicago). Specific cytotoxic titers are expressed as the reciprocal of the dilution of antiserum that lysed 50% of lymph node target cells. An antiserum directed against H-2' specificity H-2.23 gave a cytotoxicity reciprocal titer of 96.
Hemagglutinins of the four groups of sera obtained from B1O.D2 mice were assayed by the method of Stimpfling et al.
(9).
Tumors. The ascitic form of Sarcoma I was obtained originally from Dr. N. Kaliss, Jackson Laboratory and was carried by intraperitoneal passage in A/J strain mice. The enhanceability of this tumor has been reported in several studies (10) (11) (12) . The ascites form of tumor YAA-C1 was obtained from Dr. K. E. Hellstr6m (13) . It is a reticulum-cell sarcoma of an A-strain origin that was induced by Moloney leukemogenic virus and acquired a polyoma-specific (tumor-specific trasnplantation, TST) antigen after repeated infections with polyoma virus. Tumor Py 89 is a fibrosarcoma induced in C57BL/KaLw mice by polyoma virus and has been adapted to in vitro growth (14) . All three tumors grew progressively and killed their syngeneic recipients.
Preparation and Incubation of Tumor Cells. YAA-C1 and Sarcoma I ascites cells were washed twice in medium 199. 106 cells of tumor YAA-C1 or 6.2 X 106 cells of Sarcoma I in 0.2 ml of medium 199 were inoculated subcutaneously into each mouse. The Py 89 cells that were propagated in vitro, were trypsinized and inoculated subcutaneously at a concentration of 5 X 106 cells per mouse in 0.1 ml of medium 199. with 0.2 ml of 0.01 M Tris -HCl buffer (pH 8.4)-0.15 M NaClFreund's adjuvant. Booster inoculations were given 2 weeks later; the same concentrations and volumes of inoculum were used without Freund's adjuvant. All mice were then challenged subcutaneously, 10 days after the booster inoculations, with YAA-C1 ascites cells. YAA-C1 tumor cells grew in all CBA hosts to a size of about 10 X 10 X 20 mm, by the eighth day after grafting. Subsequently, either progressive growth and death of mice or complete regression was observed; in many individuals, however, a delayed regression occurred, even after the tumors attained substantially large sizes. Table 1 shows that both crude membrane material and fraction 2 induced the capacity of nearly 50% of the CBA recipients to support the growth of YAA-C1 cells, which caused death of the host from the tumor. Equal numbers of female and male mice were used; the results were combined in Table 1 . In two groups, however, not shown separately in the table, a higher susceptibility of females to progressive growth and a delayed regression of the tumor was observed. 25 days after challenge with the tumor, all six nonimmunized (adjuvant inoculated) CBA female mice completely rejected their tumors; eight female mice that were treated with fraction 2 showed progressively growing neoplasms. This contrasts to the usually greater susceptibility of male recipients to enhancement and correlates with their usually less vigorous immune response to transplantation antigens. We did not observe however, in our previous study, a lowered immune responsiveness among CBA males, which were injected with fraction 2, to allogeneic (Strain A) skin grafts. In the present work, the higher concentrations of cellmembrane preparations and fraction 2 (100 ,g) were given to females, which may account for their heightened susceptibility to YAA-C1 cells.
CBA recipients, treated with 50 or 100 j1g of fraction 3, did not differ from untreated controls, which were injected with Freund's adjuvant alone. Fig. 1A shows comparative rates of regression over a 75 day period.
That active immunologic enhancement may account for the increased frequency of progressive tumor growth and the delayed regressions in the two groups of CBA recipients of cell-membrane and fraction-2 preparations (both contain H-2 isoantigens) is suggested by the results shown in That enhanced growth of Sarcoma I and YAA-C1 tumors, provided by our soluble H-2a alloantigen preparation is specific, is shown by the results in Table 4 . Fibrosarcoma Py 89 of C57BL origin was easily enhanced in allogeneic B10.D2 and CBA mice by passive transfer of Anti-C57BL or anti-Py 89 antisera that were produced in appropriated strains (groups 2 and 6), yet antisera produced in B1O.D2 and CBA mice against the H-2a alloantigens of the soluble fraction 2 did not provide enhancement (groups 1 and 4).
DISCUSSION
We have solubilized H-2 antigens of A/J (H-2a) spleen cells by limited papain digestion. The partially purified fraction 2 eluted from a Sephadex G-150 column has been shown to be complete with respect to all H-2 serologic specificities tested [1,3,4,5,11,23, and 28] and, in addition, to be immunogenic as measured by a sensitive skin graft-rejection assay; H-2 activity was confined to fraction 2, found in the included volume (5). The association of alloantigenic specificities and transplantation antigens that are controlled by H-2 locus, suggests that both are present on the same molecule. Our previous studies did not provide evidence for the completeness of the solubilized H-2 transplantation antigens. One test for the completeness of these antigens is the induction of immunologic enhancement. Enhancement may be either active, induced by immunization of the graft recipient with donor tissue or passive, by transfer to the recipient of serum produced by immunization of another individual with donor antigens. A strict temporal pattern is necessary to realize optimal enhancement; challenge with the tumor should occur 2-4 weeks after sensitization (11) , at a time when cytotoxic or hemagglutinating antibodies reach peak titers. The enhancing potency of antisera appears to be positively correlated with these antibody titers (10) . The enhancement, detected most effectively with allogeneic tumor grafting, results from the presence of alloantibody directed, principally against the H-2 transplantation antigens (11, 15) Subcutaneous growths of tumor Py 89 in groups 2 and 4 were much larger and had attained a size of >15 mm at the largest diameter, 28 days after grafting. corresponding antibodies, thus enhancement is shown to be immunologically specific (6, 7) .
The present studies were designed to test the ability of solubilized H-2 transplantation antigens, derived from strain A/J (H-2a) to enhance the growth of two tumor allografts: YAA-C1 (H-2a) and Sarcoma I (H-2a) in CBA (H-2k) and BLO.D2 (H-2d) recipients, respectively. The experimental scheme was similar to that described initially by Kaliss (11) .
The experiments show that specific immunological enhancement has been achieved on the basis of the following criteria:
(a) Active enhancement was noted in both systems studied with crude membrane material or fraction 2 but not with the fraction 3; both crude membrane preparation and fraction 2 are known from (5) to contain H-2 antigens. The soluble fraction 3 that was assayed previously was shown to be immunogenic in causing strain A (H-2a) skin-graft rejection in CBA (H-2k) recipients, but was not immunogenic when congenic recipients, differing only at the H-2 locus, were used (1). This observation suggested that the transplantation antigens in this fraction were controlled by loci other than H-2. The absence of enhancing capacity in fraction 3 further confirms this conclusion and reemphasizes the major role of H-2 antigens in immunologic enhancement. Cytotoxic and/or hemagglutinating antibodies were detected in the sera of those recipients of the cell-membrane preparation or frac-20. tion 2. Proc. Nat. Acad. Sci. USA 68 (1971) (b) Passively transferred antiserum from recipients of the cell-membrane material or fraction 2, but not from recipients of fraction 3, enhanced the growth of YAA-C1 and Sarcoma I tumors in CBA and B1O.D2 mice, respectively; passive immunization was more effective in enhancement of the growth of Sarcoma I.
(c) Enhancement by solubilized H-2a antigens was specific. Passive transfer of antisera from mice immunized with fraction 2 did not enhance tumor Py 89 of C57BL (H-2b) origin; yet, the tumor was readily enhanced by antisera produced by H-2b antigens in suitable recipients (Table 4) .
Although these results demonstrate that all important antigenic determinants (H-2a) have been recovered in the soluble material, this does not imply that the transplantation antigen molecules are identical to those present in situ on the membrane of the intact cell. Fragmentation may have occurred, despite the maintenance of immunogenicity of all determinants. Fragmentation may be demonstrated after further purification, characterization, and biologic tests of fraction 2. A critical test is the induction of tolerance.
Nathenson and coworkers (24) have shown that prolonged papain digestion of membranes from mouse spleen cells (H-2b and H-2d genotypes) results in fragmentation of H-2 alloantigenic specificities. Although these antigen fragments, partially purified by Sephadex chromatography and polyacrylamide disc electrophoresis, retain their ability to inhibit immune cytolysis of certain alloantigens of limited specificity, they have not been shown to possess true biologic activity. Only a relatively crude papain digest has produced accelerated rejection of allogeneic skin grafts in strain combinations in which differences of loci other than H-2 could not be excluded (16) . In later studies (17) by use of aliquots of classes I and II, fragments bearing different series of H-2 specification were demonstrated to have immunogenicty after Sephadex G-150 and carboxymethyl Sephadex purification.
In contrast, the present study demonstrates that when proteolysis by papain is carefully controlled, material from A/J spleen cells, purified by Sephadex G-150 chromatography and confined to a single peak, retains all H-2a alloantigenic specificities, and full serologic and biologic activity. The advantage of limited papain digestion will be confirmed if the methods used here can be successfully applied to the solubilization and purification of H-2 transplantation antigens of other strains of mice.
